Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)

被引：0
|
作者：
Badawy, Mohmed [1 ]
Johnson, Geoffrey B. [1 ]
Hobday, Timothy [1 ]
Packard, Annie T. [1 ]
Jain, Manoj [2 ]
Halfdanarson, Thorvardur R. [1 ]
Young, Jason R. [1 ]
Thorpe, Matthew P. [1 ]
Eiring, Rachel A. [1 ]
Kendi, Ayse Tuba [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
PANCREAS | 2022年 / 51卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
C-24
引用
收藏
页码：E42 / E42
页数：1
相关论文
共 50 条
  • [21] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors
    Jahn, U. M. M.
    Jahn, U. M.
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Velikyan, I.
    Fross-Baron, K.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S61 - S62
  • [22] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 177 - 182
  • [23] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [24] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599
  • [25] Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM)
    Thakral, Parul
    Sen, Ishita
    Pant, Vineet
    Gupta, Santosh Kumar
    Dureja, Sugandha
    Kumari, Jyotsna
    Kumar, Sunil
    Pallavi
    Malasani, Vindhya
    BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091):
  • [26] Update: Edmonton Lu-177 Protocol (Induction and Maintenance Regimen) Improves Progression Free Survival (PFS) in Patients with Advanced Neuroendocrine Tumours (NETs)
    McEwan, A. J. B.
    Wieler, M.
    Murray, D.
    Sawyer, M. B.
    Morrish, D.
    Schaitel, B. A.
    Schrader, L. D.
    McMullen, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S156 - S156
  • [27] A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)
    Ross, Erin
    Ram, Lydia
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [28] Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors
    Kim K.
    Kim S.-J.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (3) : 208 - 215
  • [29] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
  • [30] Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Parghane, Rahul V.
    Talole, Sanjay
    Prabhash, Kumar
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 428 - 435
12345